Original Article

You have free access to this content

Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma†

Results of a large phase 2 study

  1. David J. Vaughn MD1,‡,*,
  2. Sandy Srinivas MD2,
  3. Walter M. Stadler MD3,
  4. Roberto Pili MD4,
  5. Daniel Petrylak MD5,
  6. Cora N. Sternberg MD6,
  7. David C. Smith MD7,
  8. Sarah Ringuette MD8,
  9. Edwin de Wit MD8,
  10. Virginie Pautret MD9,
  11. Claude George MD10

Article first published online: 17 JUN 2009

DOI: 10.1002/cncr.24460

Issue

Cancer

Cancer

Volume 115, Issue 18, pages 4110–4117, 15 September 2009

Additional Information

How to Cite

Vaughn, D. J., Srinivas, S., Stadler, W. M., Pili, R., Petrylak, D., Sternberg, C. N., Smith, D. C., Ringuette, S., de Wit, E., Pautret, V. and George, C. (2009), Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma. Cancer, 115: 4110–4117. doi: 10.1002/cncr.24460

Author Information

  1. 1

    Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

  2. 2

    Department of Medicine, Stanford University, Stanford, California

  3. 3

    Department of Medicine, University of Chicago, Chicago, Illinois

  4. 4

    Department of Medicine, Johns Hopkins University, Baltimore, Maryland

  5. 5

    Department of Medicine, Columbia University, New York, New York

  6. 6

    Department of Medicine, San Camillo Forlanini Hospital, Rome, Italy

  7. 7

    Department of Medicine, University of Michigan, Ann Arbor, Michigan

  8. 8

    Bristol-Myers Squibb, Wallingford, Connecticut

  9. 9

    Bristol-Myers Squibb, Braine L'Alleud, Belgium

  10. 10

    Bristol-Myers Squibb, Princeton, New Jersey

  1. ‡

    Fax: (215) 662-7804

*Abramson Cancer Center of the University of Pennsylvania, 16 Penn Tower, 300 Spruce Street, Philadelphia, PA 19104

  1. †

    Presented in part at the 14th European Cancer Conference, Barcelona, Spain, September 23-27, 2007; and the American Society of Clinical Oncology Genitourinary Cancers Symposium, San Francisco, California, February 14-16, 2008.

Publication History

  1. Issue published online: 4 SEP 2009
  2. Article first published online: 17 JUN 2009
  3. Manuscript Accepted: 26 JAN 2009
  4. Manuscript Revised: 16 JAN 2009
  5. Manuscript Received: 25 NOV 2008

Funded by

  • Bristol-Myers Squibb

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (162K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Kazutaka Saito, Shinji Urakami, Yoshinobu Komai, Yosuke Yasuda, Yuichi Kubo, Shinichi Kitsukawa, Yuhei Okubo, Shinya Yamamoto, Junji Yonese, Iwao Fukui, Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin, BJU International, 2012, 109, 12
    Direct Link:
  2. 2
    Daniel Castellano, Joan Carles, Emilio Esteban, José Manuel Trigo, Miguel Ángel Climent, José Pablo Maroto, Xavier García del Muro, Albert Font, Luis Paz-Ares, José Ángel Arranz, Joaquim Bellmunt, Recommendations for the optimal management of early and advanced urothelial carcinoma, Cancer Treatment Reviews, 2012, 38, 5, 431

    CrossRef

  3. 3
    M. Racioppi, D. DÂ’Agostino, A. Totaro, F. Pinto, E. Sacco, A. DÂ’Addessi, F. Marangi, G. Palermo, P.F. Bassi, Value of Current Chemotherapy and Surgery in Advanced and Metastatic Bladder Cancer, Urologia Internationalis, 2012, 88, 3, 249

    CrossRef

  4. 4
    Luis Miguel Anton Aparicio, Enrique Grande Pulido, Guadalupe Aparicio Gallego, Vinflunine, Anti-Cancer Drugs, 2012, 23, 1, 1

    CrossRef

  5. 5
    Gillian M. Keating, James E. Frampton, Marit D. Moen, Vinflunine: a guide to its use in bladder cancer, Drugs & Therapy Perspectives, 2012, 28, 2, 1

    CrossRef

  6. 6
    Yozo Mitsui, Hiroaki Yasumoto, Naoko Arichi, Satoshi Honda, Hiroaki Shiina, Mikio Igawa, Current chemotherapeutic strategies against bladder cancer, International Urology and Nephrology, 2011, 44, 2, 431

    CrossRef

  7. 7
    Amy Q Lei, Liang Cheng, Chong-xian Pan, Current treatment of metastatic bladder cancer and future directions, Expert Review of Anticancer Therapy, 2011, 11, 12, 1851

    CrossRef

  8. 8
    Evangelos Bournakis, Meletios A Dimopoulos, Aristotle Bamias, Management of advanced bladder cancer in patients with impaired renal function, Expert Review of Anticancer Therapy, 2011, 11, 6, 931

    CrossRef

  9. 9
    Elizabeth A Guancial, Dipanjan Chowdhury, Jonathan E Rosenberg, Personalized therapy for urothelial cancer: review of the clinical evidence, Clinical Investigation, 2011, 1, 4, 543

    CrossRef

  10. 10
    Jae-Lyun Lee, Jin-Hee Ahn, Se Hoon Park, Ho Young Lim, Jung Hye Kwon, Shin Ahn, Cheryn Song, Jun Hyuk Hong, Choung-Soo Kim, Hanjong Ahn, Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum, Investigational New Drugs, 2011,

    CrossRef

  11. 11
    J. Bellmunt, T. K. Choueiri, F. A. B. Schutz, J. E. Rosenberg, Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls, Annals of Oncology, 2011, 22, 2, 245

    CrossRef

  12. 12
    Holger Gerullis, Thorsten Ecke, Christoph Eimer, Mohamed Wishahi, Thomas Otto, Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma, Anti-Cancer Drugs, 2011, 22, 1, 9

    CrossRef

  13. 13
    Ronac Mamtani, David J Vaughn, Vinflunine in the treatment of advanced bladder cancer, Expert Review of Anticancer Therapy, 2011, 11, 1, 13

    CrossRef

  14. 14
    Fabio AB Schutz, Joaquim Bellmunt, Jonathan E Rosenberg, Toni K Choueiri, Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid, Expert Opinion on Drug Safety, 2011, 10, 4, 645

    CrossRef

  15. 15
    Todd M Morgan, Peter E Clark, Bladder cancer, Current Opinion in Oncology, 2010, 22, 3, 242

    CrossRef

  16. 16
    J. Bellmunt, M. Guix, New agents for bladder cancer, Annals of Oncology, 2010, 21, Supplement 7, vii56

    CrossRef

  17. 17
    Gopa Iyer, Matthew I Milowsky, Dean F Bajorin, Novel strategies for treating relapsed/refractory urothelial carcinoma, Expert Review of Anticancer Therapy, 2010, 10, 12, 1917

    CrossRef

  18. 18
    Guru Sonpavde, Cora N Sternberg, Jonathan E Rosenberg, Noah M Hahn, Matthew D Galsky, Nicholas J Vogelzang, Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium, The Lancet Oncology, 2010, 11, 9, 861

    CrossRef

  19. 19
    François Audenet, David R. Yates, Olivier Cussenot, Morgan Rouprêt, The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC), Urologic Oncology: Seminars and Original Investigations, 2010,

    CrossRef

  20. 20
    James E. Frampton, Marit D. Moen, Vinflunine, Drugs, 2010, 70, 10, 1283

    CrossRef

  21. 21
    &NA;, Vinflunine: a guide to its use in bladder cancer, Drugs & Therapy Perspectives, 2010, 26, 12, 1

    CrossRef

View Full Article (HTML) Get PDF (162K)